Effect of Sibeprenlimab on eGFR in Adults With IgA Nephropathy: A Prespecified Interim Analysis of the VISIONARY Phase 3 Trial
June 3, 2026 | 63rd ERA Congress
V. Perkovic,1 J. Hafkin,2,a J. Xia,2 J. Barratt,3 on behalf of the VISIONARY Steering Committee